Corby Fink
Overview
Explore the profile of Corby Fink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mumby M, Prodger J, Hackman J, Saraf S, Zhu X, Ferreira R, et al.
Lancet Microbe
. 2025 Mar;
:101018.
PMID: 40088911
Background: The persistence of a replication-competent latent viral reservoir (RC-LVR) during antiretroviral therapy (ART) is a barrier to the development of a cure for HIV-1, but the role of viral...
2.
Blythe E, Barreira C, Fink C, Brown A, Weaver L, Dekaban G
Antib Ther
. 2025 Jan;
8(1):26-39.
PMID: 39839909
Background: Immunomodulatory agents targeting the CD11d/CD18 integrin are in development for the treatment of several pathophysiologies including neurotrauma, sepsis, and atherosclerosis. Murine anti-human CD11d therapeutic antibodies have successfully improved neurological...
3.
Taefehshokr N, Lac A, Vrieze A, Dickson B, Guo P, Jung C, et al.
J Cell Sci
. 2024 Apr;
137(10).
PMID: 38682259
SARS-CoV-2 interferes with antigen presentation by downregulating major histocompatibility complex (MHC) II on antigen-presenting cells, but the mechanism mediating this process is unelucidated. Herein, analysis of protein and gene expression...
4.
Fink C, Gevaert J, Barrett J, Dikeakos J, Foster P, Dekaban G
Eur Radiol Exp
. 2023 Aug;
7(1):42.
PMID: 37580614
Background: Despite widespread study of dendritic cell (DC)-based cancer immunotherapies, the in vivo postinjection fate of DC remains largely unknown. Due in part to a lack of quantifiable imaging modalities,...
5.
Benlarbi M, Laroche G, Fink C, Fu K, Mulloy R, Phan A, et al.
iScience
. 2022 Oct;
25(11):105316.
PMID: 36254158
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) binds to angiotensin-converting enzyme 2 (ACE2) to mediate membrane fusion via two distinct pathways: 1) a surface, serine protease-dependent or...
6.
Lurie A, Fink C, Gosselin G, Dekaban G, Dikeakos J
Virologie (Montrouge)
. 2022 Jun;
26(1):17-33.
PMID: 35766095
Antiretroviral therapy can control human immunodeficiency virus type 1 (HIV-1) replication in people living with HIV; however, these treatments are not curative and no practical approach for an HIV-1 cure...
7.
Lurie A, Fink C, Gosselin G, Dekaban G, Dikeakos J
Virologie (Montrouge)
. 2022 Jun;
26(1):55-71.
PMID: 35766094
Résumé La thérapie anti-rétrovirale peut contrôler la réplication du virus de l'immunodéficience humaine de type 1 (VIH-1) chez les individus vivant avec le VIH. Par contre, ces traitements ne constituent...
8.
Gevaert J, Fink C, Dikeakos J, Dekaban G, Foster P
Mol Imaging Biol
. 2022 Jun;
24(6):886-897.
PMID: 35648316
Purpose: The purpose of this study was to evaluate magnetic particle imaging (MPI) as a method for the in vivo tracking of dendritic cells (DC). DC are used in cancer...
9.
Ullah I, Prevost J, Ladinsky M, Stone H, Lu M, Anand S, et al.
Immunity
. 2021 Aug;
54(9):2143-2158.e15.
PMID: 34453881
Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor the real-time effects...
10.
Ullah I, Prevost J, Ladinsky M, Stone H, Lu M, Anand S, et al.
bioRxiv
. 2021 Apr;
PMID: 33791699
Neutralizing antibodies (NAbs) are effective in treating COVID-19 but the mechanism of immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor the real-time effects...